The OIE Code therefore requires that vaccinated animals are tested serologically to show that there is no ongoing virus transmission or “circulation”, and, in case of countries wishing to recover the status of “FMD-free where vaccination is not practised”, that infected animals are not present. The OIE definition of infection would include carriers, although these are not specifically referred to. check details In the current FMD Chapter (8.6) of the OIE Code [19], the articles on surveillance (articles 42–47 and article 49) describe

the principles that should be followed, but do not specify a sampling frame or design prevalence for detecting virus transmission or infected (including carrier) animals. The EU Directive on FMD control gives a more detailed account of the post-vaccination surveillance required for EU Member States to recover the status of FMD-free where vaccination is not practiced (Supplementary Table 2, [9]). The requirement in the EU Directive to sample and test all vaccinated animals and their unvaccinated offspring (so-called “census surveillance”) arose from the view

that NSP serology should be used as a herd test [50] along with the desire to provide a high level of confidence that all carriers are detected and that limited virus transmission within herds is not overlooked by serological surveillance. This would overcome the problem Pexidartinib purchase that has led to re-emergence of infection after many years of apparent freedom, and despite targeted annual serosurveillance, in countries continuing with prophylactic mass vaccination after attainment of the status FMD-free where vaccination is

practised [7]. This approach also helps to deal with the so-called “small herd problem” in which herd-level freedom cannot be demonstrated with imperfect tests if the expected within-herd prevalence Methisazone is low, as it allows small herds to be evaluated as an amalgamated stratum rather than at the herd level [51]. The sampling requirements are set out in paragraph 3 of Article 56, although the text appears ambiguous requiring either a sampling protocol suitable for detecting a 5% in-herd prevalence with at least a 95% level of confidence or the sampling and testing of all animals in vaccinated herds. The first option is actually intended to be for non-vaccinated animals within a vaccination zone that are unlikely to show clear clinical signs (e.g. sheep and goats), but this only becomes explicit in the context of the referenced Annex III to that Directive. Both the OIE Code [19] and the EU Directive [9] require follow-up investigation of all serologically positive findings and a return to the farm to double-check for clinical evidence of FMD and to collect fresh samples from the originally sampled cohort and a number of direct contact animals.